Biotech Values

[jq1234]

Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease

http://www.drugs.com/clinical_trials/five-year-alemtuzumab-phase-2-data-shows-large-percentage-ms-patients-remain-free-clinically-active-11568.html?utm_source=feedburner&utm_medium=twitter&utm_campaign=Feed%3A+Drugscom-ClinicalTrials+%28Drugs.com+-+Clinical+Trials%29

Results of the five-year review showed:

•an estimated 65 percent of alemtuzumab-treated patients were free of clinically-active disease, compared to 27 percent of patients taking Rebif (p<0.0001). To be free of clinically-active disease, MS patients in the trial were both relapse-free and without a sustained increase in disability as measured by the Expanded Disability Status Scale (EDSS) through five years;
•an estimated 72 percent of alemtuzumab-treated patients were relapse-free compared to 41 percent of patients taking Rebif; and
•an estimated 87 percent of alemtuzumab-treated patients were free of sustained accumulation of disability compared to 62 percent of patients taking Rebif (previously reported).

“These data suggest that alemtuzumab may have great potential for MS patients,” said abstract author Cary Twyman, MD, principal Investigator, Associates in Neurology, Lexington, KY.